financetom
Business
financetom
/
Business
/
Aris Mining First-Quarter Gold Production Rises 8%
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Aris Mining First-Quarter Gold Production Rises 8%
Apr 8, 2025 2:37 PM

05:27 PM EDT, 04/08/2025 (MT Newswires) -- Aris Mining ( ARMN ) after trade Tuesday reported gold production of 54,763 ounces for the first quarter,, with 47,549 ounces from Segovia and 7,214 ounce from the Marmato Upper Mine.

The Colombian miner cited positive trends across both the Segovia and Marmato operations, with a total gold production in the quarter up 8% from 50,767 in the year-prior quarter.

The company said the first-quarter production "reflects strong operational momentum" heading into 2025, adding with the commissioning of the expanded Segovia processing facility on track for the second quarter, additional production growth is anticipated in the coming quarters.

Aris said its 2025 full-year production guidance is between 230,000-275,000 oz, with Segovia expected to produce 210,000-250,000 oz and the Marmato Upper Mine expected to contribute 20,000-25,000 oz.

"We kicked off 2025 with strong momentum, highlighting our ability to effectively execute while advancing major growth initiatives. Q1 production came in slightly ahead of our budget target reflecting a solid operational start to the year. With the expanded Segovia processing facility set to be commissioned this quarter, we are well on track to deliver on our full-year production guidance of 230,000 to 275,000 oz," chief executive Neil Woodyer said.

Aris shares closed down $0.01 to $6.06 on the Toronto Stock Exchange.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Verastem Reports Results of Potential Pancreatic Cancer Treatment, Submits Rolling New Drug Application for Rare Ovarian Cancer
Verastem Reports Results of Potential Pancreatic Cancer Treatment, Submits Rolling New Drug Application for Rare Ovarian Cancer
May 24, 2024
08:25 AM EDT, 05/24/2024 (MT Newswires) -- Verastem Oncology (VSTM) late Thursday reported that an ongoing phase 1/2 clinical trial evaluating avutometinib and defactinib in combination with gemcitabine and nab-paclitaxel in 41 patients with metastatic pancreatic cancer reached an interim partial response rate of 83%. Of 26 patients in all the trial cohorts who have had their first scan while...
E3 Lithium Narrows Q1 Loss; Company Hasn't Started Commercial Production or Generated Cash Flow
E3 Lithium Narrows Q1 Loss; Company Hasn't Started Commercial Production or Generated Cash Flow
May 24, 2024
08:25 AM EDT, 05/24/2024 (MT Newswires) -- E3 Lithium ( EEMMF ) on Friday reported a narrower loss for the first quarter even though the company has not generated revenues from operations and had an accumulated deficit of $45.2 million at the end of March. The company reported a first-quarter net loss of $2.4 million, or $0.03 per share, compared...
--Cato Keeps Quarterly Dividend at $0.17 per share, Payable June 24 to Shareholders of Record June 10
--Cato Keeps Quarterly Dividend at $0.17 per share, Payable June 24 to Shareholders of Record June 10
May 24, 2024
08:17 AM EDT, 05/24/2024 (MT Newswires) -- Price: 5.73, Change: -0.05, Percent Change: -0.87 ...
Organon, Henlius' Denosumab Biosimilar HLX14 Gets European Validation
Organon, Henlius' Denosumab Biosimilar HLX14 Gets European Validation
May 24, 2024
08:17 AM EDT, 05/24/2024 (MT Newswires) -- Organon (OGN) and Shanghai Henlius Biotech said Friday their marketing authorization applications for HLX14, a denosumab biosimilar, have been validated by the European Medicines Agency. The submissions were based on a phase 3 study comparing HLX14 with denosumab in postmenopausal women with osteoporosis, the companies said. Henlius licensed HLX14 to Organon in 2022...
Copyright 2023-2025 - www.financetom.com All Rights Reserved